{"ticker": {"uuid": "555105cb-5a62-4703-91b8-b419ded90f2c", "symbol": "CPRX", "name": "Catalyst Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/angelini-pharma-completes-acquisition-catalyst-073600135.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T07:36:00+00:00", "published_display": "16 Jul 2026 07:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Angelini wraps $4.1 billion buyout of Catalyst Pharmaceuticals (NASDAQ:CPRX) at 9x projected 2026 EBITDA", "summary": "Angelini has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals (NASDAQ:CPRX), valuing the company at roughly 9 times its estimated 2026 EBITDA. Catalyst investors received $31.50 per share in cash, a price that, when adjusted for Catalyst's estimated $861 million", "url": "https://ts2.tech/en/angelini-wraps-4-1-billion-buyout-of-catalyst-pharmaceuticals-nasdaqcprx-at-9x-projected-2026-ebitda/", "source_name": "TechStock\u00b2", "published_at": "2026-07-15T14:32:18", "published_display": "15 Jul 2026 14:32", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq moves to delist Catalyst Pharmaceuticals (Nasdaq: CPRX) common stock", "summary": "Nasdaq has initiated the process to delist Catalyst Pharmaceuticals' (CPRX) common stock from the Nasdaq Stock Market LLC, as indicated by a Form 25 notification filed under Section 12(b) of the Exchange Act. This action signifies that Nasdaq has followed its rules to remove the ", "url": "https://www.stocktitan.net/sec-filings/CPRX/25-nse-catalyst-pharmaceuticals-inc-sec-filing-bd51cbb9ce7c.html", "source_name": "Stock Titan", "published_at": "2026-07-15T14:12:18", "published_display": "15 Jul 2026 14:12", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Shows Strong Growth and a High-Quality Technical Breakout Setup", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPcUotMktJUS1RYWVJZkEzSjRBX1ZieFlnOXk0d2hYUjZrcXRacFo3M3dYOEFKNU9zTXhwYUF1b2NaMlFsZi10M3A3YXQ2czU2RnlXZGVVblBfMmZ6cndLODRKeHNORGk4VzlTbGVGWFJhZ1UwYnh5NURZU0FhaHRNOXNsZzJ2VXlZLW0wbTI1LXlhNmkzeUlnTzAyWTN4SWNick5ZandHMERtZmZadl9LdFBqSk9aeXNySUV0aUVoUXUwNmVJZDFvN2Y2VW51OHdHRW9zT0E3bklRdmtBN1pHZzdPdThoU3dLbjdN?oc=5", "source_name": "ChartMill", "published_at": "2026-07-15T10:40:30+00:00", "published_display": "15 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P Composite 1500", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPTDA3dmZtUUxzckdDZDlGSHVQb3NSWERHWjBSWjQ3WW56aXNQX2t4UXNONWpYS2FrcGlFMTlDUThBREJtMWkwWklMODZPRnRqUjRDVUctZ2p6ZVdpMkp0aERoSjdlZDVXaEM1X01vOEJhcGp3SnI3Z2xfSzQwZlNfLXJQV2tZNUxHd1hLajZ0c0Y4UzE1TTkxUHNZTHZ5N0xMdXFVMTh2NVVoSldSU2JQTV9aTFdTX0trVDd5RnJCd0JHUkR3VVE?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T00:26:14+00:00", "published_display": "15 Jul 2026 00:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 600", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNeFlYU2IxMm92eWF4dnE1UUJWcjJpZWhFeEVJTXVOTWNEOHBEWFRqLUZNZUU2bUM0RFcyRUUyWGx5N2xaMUtkT1VaRHFucUNnRGd3Zk8zS0xvSGNyZmpaa0RyYzZJU2Q2ZXNZR0JOX01TTzZrRjhPVml3T1c5VDNMNWNPSjd1cE9aNjZJWVNZSDFZYnVEbC1lMG0zWHdWZ0NERExuRWdpb2EwSDdpb1B3U0o2WGlGbGs?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T00:26:04+00:00", "published_display": "15 Jul 2026 00:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Could Be 60% Undervalued As Merger Approval Reshapes The Board", "summary": "Catalyst Pharmaceuticals (CPRX) stockholders have approved a merger agreement, leading to the resignation of all current directors once the transaction is complete. The stock has seen significant gains, with a 90-day return of 20.16% and a 5-year return of 461.96%, partly due to ", "url": "https://www.sahmcapital.com/news/content/catalyst-pharmaceuticals-cprx-could-be-60-undervalued-as-merger-approval-reshapes-the-board-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-14T15:12:19", "published_display": "14 Jul 2026 15:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 600 Health Care", "summary": "Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) was removed from the S&P 600 Health Care sector index on July 14, 2026, as reported by S&P Capital IQ. The company is a biopharmaceutical firm focused on developing and commercializing medicines for rare diseases, including FIRDAPSE", "url": "https://www.marketscreener.com/news/catalyst-pharmaceuticals-inc-nasdaqcm-cprx-dropped-from-s-p-600-health-care-ce7f5edddc8cf024", "source_name": "www.marketscreener.com", "published_at": "2026-07-14T08:26:00", "published_display": "14 Jul 2026 08:26", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger", "summary": "Catalyst Pharmaceuticals stockholders have approved the company's merger with Angelini Pharma, where Catalyst will become a wholly owned subsidiary of Angelini Pharma. The merger proposal passed with the required majority vote at a special meeting on July 8, 2026. While an adviso", "url": "https://finance.yahoo.com/markets/stocks/articles/catalyst-pharmaceuticals-stockholders-clear-angelini-100323636.html", "source_name": "Market source", "published_at": "2026-07-11T02:10:22", "published_display": "11 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solaris Energy gets S&P SmallCap 600 spot as Catalyst exits", "summary": "Solaris Energy Infrastructure (SEI) will be added to the S&P SmallCap 600 index on July 15, 2026, replacing Catalyst Pharmaceuticals (CPRX). Catalyst Pharmaceuticals is being removed from the index due to its acquisition by Angelini Pharma. This change impacts index funds and pro", "url": "https://www.stocktitan.net/news/CPRX/solaris-energy-infrastructure-set-to-join-s-p-small-cap-wof6brtshcjv.html", "source_name": "Stock Titan", "published_at": "2026-07-10T14:41:29", "published_display": "10 Jul 2026 14:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Textbook GARP Stock Delivering Affordable Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNcGxqUGM2elNQYWdWZnY4aHg2VkVrdHJVQTdXQm5PXzJleVNXUzFUcVY4U3puRG5FV2lYc2k2dEYwMHhLbXNoQzJjYThyakk4Z19yNldYV0x4UnVNZVZ1LV9qNmFsU211RTFKYnBHaEpmSmR1MmdJa0xkOHhCNXJjZXV4WVd6MkdxaVd6VjFvOG1EZ0M1Zl9NZkpkbG9DSlRON1F2SGlFcktSd0NDekQydzFMZFAyYlpleEd6a2JvR1h5a1VIZlZZOWptSGNXQnpfQ253b0pkSG1yUQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-10T11:40:33+00:00", "published_display": "10 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solaris Energy replaces Catalyst Pharmaceuticals in S&P SmallCap 600 as acquisition nears completion", "summary": "Solaris Energy Infrastructure Inc. is set to replace Catalyst Pharmaceuticals Inc. in the S&P SmallCap 600 index on July 15, 2026. This change is prompted by Angelini Pharma's impending acquisition of Catalyst Pharmaceuticals. The shuffle signifies shifts within the small-cap mar", "url": "https://pluang.com/en/news-feed/solaris-energy-infrastruktur-gabung-sp-smallcap-600", "source_name": "Pluang", "published_at": "2026-07-09T22:12:57", "published_display": "09 Jul 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Proxy filing Summary", "summary": "A special meeting is scheduled for July 8, 2026, for Catalyst Pharmaceuticals (CPRX) shareholders to vote on a proposed merger with Angelini Pharma S.p.A. Shareholders will receive $31.50 per share in cash, representing a 21% premium to the unaffected closing share price. The boa", "url": "https://quartr.com/events/catalyst-pharmaceuticals-inc-cprx-proxy-filing_onS0Hxnm", "source_name": "Quartr", "published_at": "2026-07-09T05:12:57", "published_display": "09 Jul 2026 05:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Q1 2025 earnings summary", "summary": "Catalyst Pharmaceuticals (CPRX) reported a strong Q1 2025, with net revenues increasing 43.6% year-over-year to $141.4 million, driven by FIRDAPSE and the successful launch of AGAMREE. Net income more than doubled to $56.7 million. The company reaffirmed its full-year 2025 revenu", "url": "https://quartr.com/events/catalyst-pharmaceuticals-inc-cprx-q1-2025_onS0EsgX", "source_name": "Quartr", "published_at": "2026-07-09T04:42:19", "published_display": "09 Jul 2026 04:42", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (NASDAQ: CPRX) investors back Angelini Pharma merger deal", "summary": "Catalyst Pharmaceuticals' stockholders have approved the merger agreement with Angelini Pharma, where Catalyst will become a wholly-owned subsidiary of Angelini. While the merger proposal received overwhelming support, a non-binding advisory proposal for merger-related executive ", "url": "https://www.stocktitan.net/sec-filings/CPRX/8-k-catalyst-pharmaceuticals-inc-reports-material-event-5cbef0c9b269.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:40:46", "published_display": "08 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) EGM 2026 Summary", "summary": "This article provides a summary of Catalyst Pharmaceuticals (CPRX) Extraordinary General Meeting (EGM) held on July 8, 2026. Key aspects covered include meeting procedures, board introductions, corporate governance, and confirmation of quorum. The summary also references other re", "url": "https://quartr.com/events/catalyst-pharmaceuticals-inc-cprx-egm-2026_onS0HFCW", "source_name": "Quartr", "published_at": "2026-07-08T18:40:46", "published_display": "08 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Stock Looks Fairly Valued After Phase 1 Agamree Data", "summary": "Catalyst Pharmaceuticals (CPRX) stock appears fairly valued following positive Phase 1 data for Agamree and progress with the Angelini Pharma acquisition. The stock's P/E ratio is currently in line with both the biotech sector average and its implied fair ratio, suggesting it is ", "url": "https://www.sahmcapital.com/news/content/catalyst-pharmaceuticals-cprx-stock-looks-fairly-valued-after-phase-1-agamree-data-2026-07-04", "source_name": "Sahm", "published_at": "2026-07-06T13:12:37", "published_display": "06 Jul 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data", "summary": "Catalyst Pharmaceuticals (CPRX) reported positive Phase I results for Agamree, suggesting its potential for new indications beyond Duchenne muscular dystrophy (DMD). The study indicated that Agamree offers corticosteroid benefits with less immunosuppression compared to PTC Therap", "url": "https://www.tradingview.com/news/zacks:eeb3bd63e094b:0-cprx-s-agamree-shows-potential-beyond-dmd-after-positive-phase-i-data/", "source_name": "TradingView", "published_at": "2026-07-02T13:10:09", "published_display": "02 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CPRX - Catalyst Pharmaceuticals Inc Earnings", "summary": "This article provides a detailed financial overview of Catalyst Pharmaceuticals Inc. (CPRX), including its latest stock performance, key financial metrics, earnings data, and insider/institutional ownership. It highlights the company's strong growth in sales and EPS over various ", "url": "https://finviz.com/stock?t=CPRX&ty=ea", "source_name": "Finviz", "published_at": "2026-07-02T02:09:01", "published_display": "02 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Santhera Notes Topline Results from Catalyst Pharmaceuticals\u2019 Phase 1 Clinical Study of AGAMREE\u00ae", "summary": "Santhera Pharmaceuticals announced topline results from a Phase 1 clinical study of AGAMREE\u00ae conducted by its North American partner, Catalyst Pharmaceuticals. The study in healthy adult volunteers showed that AGAMREE\u00ae delivers glucocorticoid and anti-inflammatory activity with l", "url": "https://uk.finance.yahoo.com/news/santhera-notes-topline-results-catalyst-050000668.html", "source_name": "Market source", "published_at": "2026-07-01T05:00:00", "published_display": "01 Jul 2026 05:00", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression", "summary": "Catalyst Pharmaceuticals announced positive topline results from a two-part Phase 1 study of vamorolone in healthy volunteers. The study demonstrated balanced corticosteroid activity with expected cortisol suppression and no significant immunosuppressive activity at clinical dose", "url": "https://www.stocktitan.net/sec-filings/CPRX/8-k-catalyst-pharmaceuticals-inc-reports-material-event-796ee070905c.html", "source_name": "Stock Titan", "published_at": "2026-06-30T21:18:48", "published_display": "30 Jun 2026 21:18", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vamorolone Demonstrates On-Target Glucocorticoid Activity", "summary": "Catalyst Pharmaceuticals, Inc. announced positive topline results from a Phase 1 clinical study of vamorolone in healthy adult volunteers. The study showed that vamorolone delivers on-target glucocorticoid and anti-inflammatory activity with expected cortisol suppression, but wit", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319637/0/en/vamorolone-demonstrates-on-target-glucocorticoid-activity-without-the-immunosuppression-characteristic-of-traditional-corticosteroids-at-clinical-doses.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:10:48", "published_display": "30 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst's rare-disease steroid showed immune activity without the usual suppression", "summary": "Catalyst Pharmaceuticals announced positive topline results from a Phase 1 study of vamorolone in healthy adults, demonstrating on-target glucocorticoid activity with expected cortisol suppression and without significant immunosuppression at clinical doses. The study compared vam", "url": "https://www.stocktitan.net/news/CPRX/vamorolone-demonstrates-on-target-glucocorticoid-activity-without-y1hrci0fjp82.html", "source_name": "Stock Titan", "published_at": "2026-06-30T10:39:31", "published_display": "30 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Following Strong Rare Disease Results Is The Upside Already Priced In", "summary": "Catalyst Pharmaceuticals (CPRX) has generated significant investor interest due to its strong rare-disease portfolio, which produced substantial annual revenue and net income. While the current share price of $31.42 is close to an external target, cash flow estimates suggest a 50", "url": "https://www.sahmcapital.com/news/content/catalyst-pharmaceuticals-cprx-following-strong-rare-disease-results-is-the-upside-already-priced-in-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-27T15:10:58", "published_display": "27 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Catalyst Pharmaceuticals, Inc. \u2013 NASDAQ:CPRX", "summary": "This article provides access to the \"Price to earnings forward\" financial data for Catalyst Pharmaceuticals, Inc. (CPRX) on the Nasdaq Stock Market. It's presented through the TradingView platform, which offers various financial tools and market data services. The content emphasi", "url": "https://www.tradingview.com/symbols/NASDAQ-CPRX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:09:43", "published_display": "27 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Catalyst Pharmaceuticals, Inc. \u2013 NASDAQ:CPRX", "summary": "This article displays information regarding the enterprise value to revenue forward for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX). It provides a snapshot of the company's financial data on TradingView. The content is primarily a data point without extensive analytical text.", "url": "https://www.tradingview.com/symbols/NASDAQ-CPRX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:21", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Catalyst Pharmaceuticals, Inc. \u2013 NASDAQ:CPRX", "summary": "This article provides the \"Price to sales forward\" financial metric for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX). It is presented within a financial data platform from TradingView, which also lists other company information and market data services. The content itself seems ", "url": "https://www.tradingview.com/symbols/NASDAQ-CPRX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:11:01", "published_display": "26 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Short Interest & Short Float | Updated Jun 2026", "summary": "As of June 15, 2026, Catalyst Pharmaceuticals (CPRX) had 7.95 million shares sold short, representing 7.25% of its public float, marking a 2.91% decrease from the previous report. The short interest ratio is 5.5 days to cover. This data indicates a slight decrease in bearish sent", "url": "https://www.marketbeat.com/stocks/NASDAQ/CPRX/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-25T21:39:28", "published_display": "25 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Gets Early FTC Clearance For Angelini Merger", "summary": "Catalyst Pharmaceuticals (NasdaqCM:CPRX) has received early U.S. Federal Trade Commission clearance for its proposed merger with Angelini Pharma, accelerating the regulatory review process. This clearance addresses a major regulatory hurdle for the acquisition, which is still con", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-pharmaceuticals-cprx-gets-early-ftc-clearance-for-a", "source_name": "Simply Wall Street", "published_at": "2026-06-25T08:10:34", "published_display": "25 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX", "summary": "Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. The law firm is scrutinizing whether the offered price of $31.50 per share adequately values the company and if the sales process was fair ", "url": "https://www.businesswire.com/news/home/20260624581199/en/Catalyst-Pharmaceuticals-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Catalyst-Pharmaceuticals-Inc.---CPRX", "source_name": "Business Wire", "published_at": "2026-06-24T18:39:35", "published_display": "24 Jun 2026 18:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals to Be Acquired by Angelini Pharma in All-Cash Merger \u2013 Key Details from 8-K Filing", "summary": "Catalyst Pharmaceuticals, Inc. has announced a definitive merger agreement with Angelini Pharma S.p.A., where Catalyst will become a wholly-owned subsidiary of Angelini Pharma. The all-cash transaction is expected to close in the third quarter of 2026, subject to customary closin", "url": "https://www.minichart.com.sg/2026/06/24/catalyst-pharmaceuticals-to-be-acquired-by-angelini-pharma-in-all-cash-merger-key-details-from-8-k-filing/", "source_name": "Minichart", "published_at": "2026-06-24T01:39:36", "published_display": "24 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals merger cleared HSR waiting period as closing targets Q3 2026", "summary": "Catalyst Pharmaceuticals announced that the FTC granted early termination of the HSR waiting period for its merger with Angelini Pharma. This regulatory clearance, granted on June 16, 2026, paves the way for the merger, which is expected to close in Q3 2026, subject to customary ", "url": "https://www.tradingview.com/news/tradingview:ac6710b85ee91:0-catalyst-pharmaceuticals-merger-cleared-hsr-waiting-period-as-closing-targets-q3-2026/", "source_name": "TradingView", "published_at": "2026-06-23T21:10:58", "published_display": "23 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOTkY3M1RhV2VaY25Fb1BDSWRmSWxDNTNXMnczT3JGd2JZVWJzcFJPc3JOaW1QWUttRXFNZ0RiV1dIeVVkYWZScUhFVi1PSnVqcjVuRzRqdEpGOUhtdW94VHVmdFlHNG9KOUhSX1dVZHFPNVY2UnRYOWpFRkZqbzE3Y2EwWjU0Z0doRHdhekR2T1ZVdw?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOaGx3REtjYzNHbEJ2WUFQblh3STF4blV3R1RhejhZNHVVUGFEU1djR2txY0xWVmNicDhUdGk5MkF1blVoTjkxUDRIRlBDNS02NW16a1E5c2c4dXBVQWtNMnFYbHdXS29EWWdfTVhldEc4Zy02ZEFWa29YTkJkRTRfcDdBVmdoWUhSb20xRExFNWhjN29yVEN1WkxiU2RWbWItRGxYUVdkNTh2eGJHcnN1MUxlWWVoSnl4REhOMVRVZnJtZw?oc=5", "source_name": "TradingView", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Catalyst Pharmaceuticals stock (US14888U1016): Angelini Pharma to buy CPRX for $4.1 billion in cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPTGVCNGMxUUR1eTIyRFhEa3pjQXpTTHFpVTB4YVRVSGNkeDl3elE3SnUwUnlTTWZnd3VuTldyYW5TcG93a1RIRUsxS1VqUmRTVnlwLTkzVUI5MHAtVDlmNGFPUUNnTTVjOWlXMlJkdHMxQkcwNVlJYVlPZmVpMnBfTmZDTURwQUs2TERoeEJxLUVNTTgxUnB2a1lSa2RCYThJekVRcTVTZXZNOXNVSUlTdGk5M1dhTnlHTDlzN0ItOC1QbWdFanpMMU5R?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE1aUlhjcUFFaWozUjNSOEY1VFN2YnNyWlM0ZVVtQnQtUkZuMWpZZXpwRUhpTlpjdUtVaEU1QzJtUmdzSGsxSHg3UThxZThCNVRkSXc3MHNySUJkNXZRM25hRTZYd3hWY0dEczlKY0gtU3RCRVNxSXh0VXpiSVZHV0E?oc=5", "source_name": "qz.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Angelini to Expand into US Rare Disease Market with Catalyst Acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNSmlVc29vT0I5eWp1X0VLUmZJdkNpRzVNVTJvR2g1TWNJXzVfaEEwQ3lBdXV4S0lWTDR4Z2M1QU16VU5xOUVmOWVpUWZRdm12VGRwSVdIdGxXMXZTbU1WRUxieVRUamt6dDVXOEcyS2xjYm0tTGlzc0M2QXJrWFZtZU84Vms1bm1nbFk0ZHNNNUNiTmxFaDVKV2x1WWp1bmltTndzOEI5Mi1xeW0zMThrRVFBWDVwZ2M?oc=5", "source_name": "Pharmaceutical Commerce", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Angelini finds Catalyst for its US growth ambitions with $4.1B buyout", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPVmUzTHMzeXpKRTF2c0VTLTFnaUh6T0JBbUhlNEtDaUVvUV9MWVVoanYxazlYR190YkFiX3d6ZlowZ2xJZ090cHdYUmNpeW04MkRxdUk5Rl9MODVJQUN3bVQtUWpZbDlFd1JuU1pYYzdNOXI2eFFDSkZwbTBlY3FoSHJqN1JsaVFMSHRtOXg0R1l3d250T25oTGV3?oc=5", "source_name": "Fierce Pharma", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPbjZTMHRYSWp1aHVtSy1uMXphbm5sTDZwRVNPNU9QZy1GUUV6M1dRaXB3UnhMZGNuUzY5eEJ0ak1aNjlvRmFnY09OWkFGRDRkUEI1bmpIQU1fTTBpQ1ZTQVlZU24tQlhzcnJNOXdhTXFISl9XOUNWTDZ5Q1kzVVhPalhTZEhZc1NhRmM3U3NPcFBhZ1UxYjJkZDg2Zw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNRF81ZHNTOGNWbFh6OTBpN01TMm5hTTRZdUtqTFZ4ZjYxeWQ5cHd6NFQ4S2JQNWg3V1ZEUmVhSW5hYVVNY1gxanVKaXlzQ05lLXFqWURILXV2OVh3RzVFdy1zb2JXanM4QU5sc09kU0N0Nkd5ODAxc0RkTnNDU1VITUNOQUo4ZE12bm5hSlZpWjEyZzVreUFsZHF4Ul91NEtrTjVhWkxSUVhsLTYwTGc?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst (CPRX) is on the Move, Here's Why the Trend Could be Sustainable", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOa3d6dFpYZmhoczNUM0Zid3NOMnlFNXRMRFZLRzNQUUdFdEZEZS1xd3ktWnl0QkcwOER2RWU0WjRkTjd1NUpSUGtvWUF2RWVYa3RwZEM5VHk4TlplcGVlYy1VMUxicXB3MG0tZHpub1Zqa05XMlY0TXJMQS1EUnp2a25lakV5WTFiLVZBaGE4ZDhTMGhTVEJYdA?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Stronger Firdapse and Agamree Momentum Require Action From Catalyst Pharmaceuticals (CPRX) Investors?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Strength Seen in Catalyst (CPRX): Can Its 6.7% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPcF8tSnhCbVV5MzNVLWktV2psOXZaM1E4NGhxaGhReExOTmxFbGJRQWJwa0ZjYVpuTE9BWnhqV2tBY1kyVjlIemxzZVhWXzc2d0NXV0JSS0w4TFVMdHpSX2ZFR19mZE81VHdERTdBVkVISS1mNy1mLWlLMVRPWmpQS3V6OE5HbUZ1X2dxdmtZRW5lVjV0MnpGZW13?oc=5", "source_name": "Market source", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQOFNTZy11MHpWc1NCaEQ0ZllCeDVMQWRnSXNKLUdCU0xSZFVnWVZpNU1BRnA3UVE2WHI5WFlJZWJaNXhvbG54ak9YZWs5cjRtM3I4MWVMRUMyVzBDUkV6QUx2SW16OG9hLVYzVTFVUnoxQmNZblgwOXZ4MlBkUk9JYjFyelhHXzVySkdOR3p4MFVXY3g5MWx3OXNhNVNERWd0RXVkNXhtUnBuWVlmOEVsNWtUWTVyRmZFSjJNcU40SXR6cUgwT0R3c2ZWeng2R05L?oc=5", "source_name": "ChartMill", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top Affordable Growth Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxORFoxUjdrR1h4VDRiZEhueDU2RDc1aURkRlV5aThITDJjY2ZRNVJ1YnZldk80VC1NeWh1NEZ1NnQ1WWt2MDdqVUNoRU9YNzZaUmQ4RTFsTW5pYUNYbkdHdTMzZ0pxUGFZV0YtRGNZaUtUT3FYYnF5REVPMXF2eTlnUTJNUW1GanpCU01lQ2QxTEQ1SC1Gcm14V1REdkQyT0VwZjdJVnZfbWIwdlZjODYwQ1dfdGUtaVJfWGU2TnVJUC0yVDB2RU92VENkaHI?oc=5", "source_name": "ChartMill", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxObmp0dXNWNW9Ub2lLMkEyUWpvbzJQMzhMRGhyV1lMb281clFDa0FZcXBKSEk4d01qcmY4QVdZV3gyNEd1RFNPR204eVJWeFBTeEVmNjg2MG1NMzlKV2JINmltWGhGM0RXSVV1czhDVWtZNXhlRmZZZTBIVVZGTGdkZktYdHdkZWlHalFjc1g1OFYySUJIcnNyeGktbG9tMWJ1V1k2NnZBV1VDbVZMNkhLa0VidTQxZEFLUXJmdUdLc3hvdkFjcmtGN19Oa3pqMmY1aEZvOXhQSzZvUnRNbmJpMUZOM3FYZjd0TXAtNzBBVFVfLVlZMUoxbzVGOHFGVE81S2t2bENhRHlQbzNZdDNZd2dLWFZKN1EtczBlYnZCX291VjdTbG9GVTJ1LTY?oc=5", "source_name": "TradingView", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Catalyst Pharmaceuticals (CPRX) Still Attractively Priced After Recent Share Price Stability?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQdk1PT0U2TnM5eHJ0TkJ0eVRmMlA3LUlMTzBpNzFlUE9MWktTYVhwUGs1Mk4zSFBXVEsyc3RSam1Fem1KUS1uX0JSVE52Tk5MQkE1R3JYV0F4Yk5BbjZ2NFBlYThld1Z1bkZFMXFVVHBVQVRwXzZkLWg5dHVWRnBRVUNkNUprd25FcmpwTWM4U20zVkdLdWp4eWp5NzAzNWhCMURfVTBlNFl5cVlIWVZ1ZmF6SQ?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNVnlmXzk4UlQ0ZW5zQmc4UHBZWkM3SjAySXpZMWlyREJIQ0VzRHdac0kweEFMY2N2TWVqUEFBVy1RRzhwU3g4XzJEdUpJZTRxWUlGdFNzelJwOENuYUFaV19pUDhHUUNJY1dPaUxNTTJXcU95d3Nmb0VyRHlPbV9RWnFGby02bDI2X1RJejczZTU4Y1dfNWJhNG5IYzZ6NVFxeU5pOEgzZ3lEOXczWXc?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQbDQ2aEYxNlo3MHlwN3hfZTZ4eFRNem9FRGd5b3ZOOWhYdmpNZmJ2azdTdURVQnh1dzNENDVQa3JRbktvNlVuc04xbmx1eXZnQk5ncW5WTHVOUjFLNDc4aFpyMU5DMC1OSE1mSlVOSERVNjJidUdvM1FPelRLQjRDdnFnNTJBU2FaN1VSVTdGNHRGZWhpME1XN2FiUU0xOFVxTFA0YUFxOC1yRnRkUXFiV3E2eUFiY1R5SGc?oc=5", "source_name": "TradingView", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPQ0ExclBkRW5FM25Kcmt3YUhleFhQQ2gtYVVJSEE0UHNhYWlvRTF4eUd1Qy01M3ZGbnVHV1NXQU43akR5TGdQMWZ1cGRzSGQ1eUdKSGlNT2Zwd0NxTmpsd0tTeXhiUG5GWWIzQWxLNlNnOWdJZ1B3XzhhaTIzaVcyc0NTVkI5d2laYUNLSlZrNF85bHRNTjdfN0dCUDB0LTQ?oc=5", "source_name": "Finviz", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs (CPRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQSG1Lb1d5Nk54Z0dlOU1JMUR5VmpycURvVXZjajlCTFgwb3g2bV9tcmloZ1A1aF9IWTlZMDhfZThvcjZfNjJjVngyWWRnQmJ6SXJiWUprSWlSUTVQVm5CNFlTQlhmRFRFb2ZERDAzQnBkcklTblNsenAyTGtMTzA5MFlTckJvLUI5NnJfY2YzMm9rblU0UGQ4a1N5aDQ3T0ZxMFNHdWJRRXhTeE5Wbkt1UGp1M0tad0I3dFotYmtR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/angelini-pharma-completes-acquisition-catalyst-073600135.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T07:36:00+00:00", "published_display": "16 Jul 2026 07:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Angelini wraps $4.1 billion buyout of Catalyst Pharmaceuticals (NASDAQ:CPRX) at 9x projected 2026 EBITDA", "summary": "Angelini has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals (NASDAQ:CPRX), valuing the company at roughly 9 times its estimated 2026 EBITDA. Catalyst investors received $31.50 per share in cash, a price that, when adjusted for Catalyst's estimated $861 million", "url": "https://ts2.tech/en/angelini-wraps-4-1-billion-buyout-of-catalyst-pharmaceuticals-nasdaqcprx-at-9x-projected-2026-ebitda/", "source_name": "TechStock\u00b2", "published_at": "2026-07-15T14:32:18", "published_display": "15 Jul 2026 14:32", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq moves to delist Catalyst Pharmaceuticals (Nasdaq: CPRX) common stock", "summary": "Nasdaq has initiated the process to delist Catalyst Pharmaceuticals' (CPRX) common stock from the Nasdaq Stock Market LLC, as indicated by a Form 25 notification filed under Section 12(b) of the Exchange Act. This action signifies that Nasdaq has followed its rules to remove the ", "url": "https://www.stocktitan.net/sec-filings/CPRX/25-nse-catalyst-pharmaceuticals-inc-sec-filing-bd51cbb9ce7c.html", "source_name": "Stock Titan", "published_at": "2026-07-15T14:12:18", "published_display": "15 Jul 2026 14:12", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Shows Strong Growth and a High-Quality Technical Breakout Setup", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxPcUotMktJUS1RYWVJZkEzSjRBX1ZieFlnOXk0d2hYUjZrcXRacFo3M3dYOEFKNU9zTXhwYUF1b2NaMlFsZi10M3A3YXQ2czU2RnlXZGVVblBfMmZ6cndLODRKeHNORGk4VzlTbGVGWFJhZ1UwYnh5NURZU0FhaHRNOXNsZzJ2VXlZLW0wbTI1LXlhNmkzeUlnTzAyWTN4SWNick5ZandHMERtZmZadl9LdFBqSk9aeXNySUV0aUVoUXUwNmVJZDFvN2Y2VW51OHdHRW9zT0E3bklRdmtBN1pHZzdPdThoU3dLbjdN?oc=5", "source_name": "ChartMill", "published_at": "2026-07-15T10:40:30+00:00", "published_display": "15 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P Composite 1500", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPTDA3dmZtUUxzckdDZDlGSHVQb3NSWERHWjBSWjQ3WW56aXNQX2t4UXNONWpYS2FrcGlFMTlDUThBREJtMWkwWklMODZPRnRqUjRDVUctZ2p6ZVdpMkp0aERoSjdlZDVXaEM1X01vOEJhcGp3SnI3Z2xfSzQwZlNfLXJQV2tZNUxHd1hLajZ0c0Y4UzE1TTkxUHNZTHZ5N0xMdXFVMTh2NVVoSldSU2JQTV9aTFdTX0trVDd5RnJCd0JHUkR3VVE?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T00:26:14+00:00", "published_display": "15 Jul 2026 00:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 600", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNeFlYU2IxMm92eWF4dnE1UUJWcjJpZWhFeEVJTXVOTWNEOHBEWFRqLUZNZUU2bUM0RFcyRUUyWGx5N2xaMUtkT1VaRHFucUNnRGd3Zk8zS0xvSGNyZmpaa0RyYzZJU2Q2ZXNZR0JOX01TTzZrRjhPVml3T1c5VDNMNWNPSjd1cE9aNjZJWVNZSDFZYnVEbC1lMG0zWHdWZ0NERExuRWdpb2EwSDdpb1B3U0o2WGlGbGs?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-15T00:26:04+00:00", "published_display": "15 Jul 2026 00:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Could Be 60% Undervalued As Merger Approval Reshapes The Board", "summary": "Catalyst Pharmaceuticals (CPRX) stockholders have approved a merger agreement, leading to the resignation of all current directors once the transaction is complete. The stock has seen significant gains, with a 90-day return of 20.16% and a 5-year return of 461.96%, partly due to ", "url": "https://www.sahmcapital.com/news/content/catalyst-pharmaceuticals-cprx-could-be-60-undervalued-as-merger-approval-reshapes-the-board-2026-07-13", "source_name": "Sahm", "published_at": "2026-07-14T15:12:19", "published_display": "14 Jul 2026 15:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals, Inc.(NasdaqCM: CPRX) dropped from S&P 600 Health Care", "summary": "Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) was removed from the S&P 600 Health Care sector index on July 14, 2026, as reported by S&P Capital IQ. The company is a biopharmaceutical firm focused on developing and commercializing medicines for rare diseases, including FIRDAPSE", "url": "https://www.marketscreener.com/news/catalyst-pharmaceuticals-inc-nasdaqcm-cprx-dropped-from-s-p-600-health-care-ce7f5edddc8cf024", "source_name": "www.marketscreener.com", "published_at": "2026-07-14T08:26:00", "published_display": "14 Jul 2026 08:26", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger", "summary": "Catalyst Pharmaceuticals stockholders have approved the company's merger with Angelini Pharma, where Catalyst will become a wholly owned subsidiary of Angelini Pharma. The merger proposal passed with the required majority vote at a special meeting on July 8, 2026. While an adviso", "url": "https://finance.yahoo.com/markets/stocks/articles/catalyst-pharmaceuticals-stockholders-clear-angelini-100323636.html", "source_name": "Market source", "published_at": "2026-07-11T02:10:22", "published_display": "11 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solaris Energy gets S&P SmallCap 600 spot as Catalyst exits", "summary": "Solaris Energy Infrastructure (SEI) will be added to the S&P SmallCap 600 index on July 15, 2026, replacing Catalyst Pharmaceuticals (CPRX). Catalyst Pharmaceuticals is being removed from the index due to its acquisition by Angelini Pharma. This change impacts index funds and pro", "url": "https://www.stocktitan.net/news/CPRX/solaris-energy-infrastructure-set-to-join-s-p-small-cap-wof6brtshcjv.html", "source_name": "Stock Titan", "published_at": "2026-07-10T14:41:29", "published_display": "10 Jul 2026 14:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Textbook GARP Stock Delivering Affordable Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNcGxqUGM2elNQYWdWZnY4aHg2VkVrdHJVQTdXQm5PXzJleVNXUzFUcVY4U3puRG5FV2lYc2k2dEYwMHhLbXNoQzJjYThyakk4Z19yNldYV0x4UnVNZVZ1LV9qNmFsU211RTFKYnBHaEpmSmR1MmdJa0xkOHhCNXJjZXV4WVd6MkdxaVd6VjFvOG1EZ0M1Zl9NZkpkbG9DSlRON1F2SGlFcktSd0NDekQydzFMZFAyYlpleEd6a2JvR1h5a1VIZlZZOWptSGNXQnpfQ253b0pkSG1yUQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-10T11:40:33+00:00", "published_display": "10 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solaris Energy replaces Catalyst Pharmaceuticals in S&P SmallCap 600 as acquisition nears completion", "summary": "Solaris Energy Infrastructure Inc. is set to replace Catalyst Pharmaceuticals Inc. in the S&P SmallCap 600 index on July 15, 2026. This change is prompted by Angelini Pharma's impending acquisition of Catalyst Pharmaceuticals. The shuffle signifies shifts within the small-cap mar", "url": "https://pluang.com/en/news-feed/solaris-energy-infrastruktur-gabung-sp-smallcap-600", "source_name": "Pluang", "published_at": "2026-07-09T22:12:57", "published_display": "09 Jul 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Proxy filing Summary", "summary": "A special meeting is scheduled for July 8, 2026, for Catalyst Pharmaceuticals (CPRX) shareholders to vote on a proposed merger with Angelini Pharma S.p.A. Shareholders will receive $31.50 per share in cash, representing a 21% premium to the unaffected closing share price. The boa", "url": "https://quartr.com/events/catalyst-pharmaceuticals-inc-cprx-proxy-filing_onS0Hxnm", "source_name": "Quartr", "published_at": "2026-07-09T05:12:57", "published_display": "09 Jul 2026 05:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Q1 2025 earnings summary", "summary": "Catalyst Pharmaceuticals (CPRX) reported a strong Q1 2025, with net revenues increasing 43.6% year-over-year to $141.4 million, driven by FIRDAPSE and the successful launch of AGAMREE. Net income more than doubled to $56.7 million. The company reaffirmed its full-year 2025 revenu", "url": "https://quartr.com/events/catalyst-pharmaceuticals-inc-cprx-q1-2025_onS0EsgX", "source_name": "Quartr", "published_at": "2026-07-09T04:42:19", "published_display": "09 Jul 2026 04:42", "sentiment": "positive", "sentiment_pct": 87, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (NASDAQ: CPRX) investors back Angelini Pharma merger deal", "summary": "Catalyst Pharmaceuticals' stockholders have approved the merger agreement with Angelini Pharma, where Catalyst will become a wholly-owned subsidiary of Angelini. While the merger proposal received overwhelming support, a non-binding advisory proposal for merger-related executive ", "url": "https://www.stocktitan.net/sec-filings/CPRX/8-k-catalyst-pharmaceuticals-inc-reports-material-event-5cbef0c9b269.html", "source_name": "Stock Titan", "published_at": "2026-07-08T21:40:46", "published_display": "08 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) EGM 2026 Summary", "summary": "This article provides a summary of Catalyst Pharmaceuticals (CPRX) Extraordinary General Meeting (EGM) held on July 8, 2026. Key aspects covered include meeting procedures, board introductions, corporate governance, and confirmation of quorum. The summary also references other re", "url": "https://quartr.com/events/catalyst-pharmaceuticals-inc-cprx-egm-2026_onS0HFCW", "source_name": "Quartr", "published_at": "2026-07-08T18:40:46", "published_display": "08 Jul 2026 18:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Stock Looks Fairly Valued After Phase 1 Agamree Data", "summary": "Catalyst Pharmaceuticals (CPRX) stock appears fairly valued following positive Phase 1 data for Agamree and progress with the Angelini Pharma acquisition. The stock's P/E ratio is currently in line with both the biotech sector average and its implied fair ratio, suggesting it is ", "url": "https://www.sahmcapital.com/news/content/catalyst-pharmaceuticals-cprx-stock-looks-fairly-valued-after-phase-1-agamree-data-2026-07-04", "source_name": "Sahm", "published_at": "2026-07-06T13:12:37", "published_display": "06 Jul 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data", "summary": "Catalyst Pharmaceuticals (CPRX) reported positive Phase I results for Agamree, suggesting its potential for new indications beyond Duchenne muscular dystrophy (DMD). The study indicated that Agamree offers corticosteroid benefits with less immunosuppression compared to PTC Therap", "url": "https://www.tradingview.com/news/zacks:eeb3bd63e094b:0-cprx-s-agamree-shows-potential-beyond-dmd-after-positive-phase-i-data/", "source_name": "TradingView", "published_at": "2026-07-02T13:10:09", "published_display": "02 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CPRX - Catalyst Pharmaceuticals Inc Earnings", "summary": "This article provides a detailed financial overview of Catalyst Pharmaceuticals Inc. (CPRX), including its latest stock performance, key financial metrics, earnings data, and insider/institutional ownership. It highlights the company's strong growth in sales and EPS over various ", "url": "https://finviz.com/stock?t=CPRX&ty=ea", "source_name": "Finviz", "published_at": "2026-07-02T02:09:01", "published_display": "02 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Santhera Notes Topline Results from Catalyst Pharmaceuticals\u2019 Phase 1 Clinical Study of AGAMREE\u00ae", "summary": "Santhera Pharmaceuticals announced topline results from a Phase 1 clinical study of AGAMREE\u00ae conducted by its North American partner, Catalyst Pharmaceuticals. The study in healthy adult volunteers showed that AGAMREE\u00ae delivers glucocorticoid and anti-inflammatory activity with l", "url": "https://uk.finance.yahoo.com/news/santhera-notes-topline-results-catalyst-050000668.html", "source_name": "Market source", "published_at": "2026-07-01T05:00:00", "published_display": "01 Jul 2026 05:00", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression", "summary": "Catalyst Pharmaceuticals announced positive topline results from a two-part Phase 1 study of vamorolone in healthy volunteers. The study demonstrated balanced corticosteroid activity with expected cortisol suppression and no significant immunosuppressive activity at clinical dose", "url": "https://www.stocktitan.net/sec-filings/CPRX/8-k-catalyst-pharmaceuticals-inc-reports-material-event-796ee070905c.html", "source_name": "Stock Titan", "published_at": "2026-06-30T21:18:48", "published_display": "30 Jun 2026 21:18", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vamorolone Demonstrates On-Target Glucocorticoid Activity", "summary": "Catalyst Pharmaceuticals, Inc. announced positive topline results from a Phase 1 clinical study of vamorolone in healthy adult volunteers. The study showed that vamorolone delivers on-target glucocorticoid and anti-inflammatory activity with expected cortisol suppression, but wit", "url": "https://www.globenewswire.com/news-release/2026/06/30/3319637/0/en/vamorolone-demonstrates-on-target-glucocorticoid-activity-without-the-immunosuppression-characteristic-of-traditional-corticosteroids-at-clinical-doses.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:10:48", "published_display": "30 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst's rare-disease steroid showed immune activity without the usual suppression", "summary": "Catalyst Pharmaceuticals announced positive topline results from a Phase 1 study of vamorolone in healthy adults, demonstrating on-target glucocorticoid activity with expected cortisol suppression and without significant immunosuppression at clinical doses. The study compared vam", "url": "https://www.stocktitan.net/news/CPRX/vamorolone-demonstrates-on-target-glucocorticoid-activity-without-y1hrci0fjp82.html", "source_name": "Stock Titan", "published_at": "2026-06-30T10:39:31", "published_display": "30 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Following Strong Rare Disease Results Is The Upside Already Priced In", "summary": "Catalyst Pharmaceuticals (CPRX) has generated significant investor interest due to its strong rare-disease portfolio, which produced substantial annual revenue and net income. While the current share price of $31.42 is close to an external target, cash flow estimates suggest a 50", "url": "https://www.sahmcapital.com/news/content/catalyst-pharmaceuticals-cprx-following-strong-rare-disease-results-is-the-upside-already-priced-in-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-27T15:10:58", "published_display": "27 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Catalyst Pharmaceuticals, Inc. \u2013 NASDAQ:CPRX", "summary": "This article provides access to the \"Price to earnings forward\" financial data for Catalyst Pharmaceuticals, Inc. (CPRX) on the Nasdaq Stock Market. It's presented through the TradingView platform, which offers various financial tools and market data services. The content emphasi", "url": "https://www.tradingview.com/symbols/NASDAQ-CPRX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:09:43", "published_display": "27 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Catalyst Pharmaceuticals, Inc. \u2013 NASDAQ:CPRX", "summary": "This article displays information regarding the enterprise value to revenue forward for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX). It provides a snapshot of the company's financial data on TradingView. The content is primarily a data point without extensive analytical text.", "url": "https://www.tradingview.com/symbols/NASDAQ-CPRX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:21", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Catalyst Pharmaceuticals, Inc. \u2013 NASDAQ:CPRX", "summary": "This article provides the \"Price to sales forward\" financial metric for Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX). It is presented within a financial data platform from TradingView, which also lists other company information and market data services. The content itself seems ", "url": "https://www.tradingview.com/symbols/NASDAQ-CPRX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:11:01", "published_display": "26 Jun 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Short Interest & Short Float | Updated Jun 2026", "summary": "As of June 15, 2026, Catalyst Pharmaceuticals (CPRX) had 7.95 million shares sold short, representing 7.25% of its public float, marking a 2.91% decrease from the previous report. The short interest ratio is 5.5 days to cover. This data indicates a slight decrease in bearish sent", "url": "https://www.marketbeat.com/stocks/NASDAQ/CPRX/short-interest/", "source_name": "MarketBeat", "published_at": "2026-06-25T21:39:28", "published_display": "25 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Gets Early FTC Clearance For Angelini Merger", "summary": "Catalyst Pharmaceuticals (NasdaqCM:CPRX) has received early U.S. Federal Trade Commission clearance for its proposed merger with Angelini Pharma, accelerating the regulatory review process. This clearance addresses a major regulatory hurdle for the acquisition, which is still con", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-pharmaceuticals-cprx-gets-early-ftc-clearance-for-a", "source_name": "Simply Wall Street", "published_at": "2026-06-25T08:10:34", "published_display": "25 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX", "summary": "Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. The law firm is scrutinizing whether the offered price of $31.50 per share adequately values the company and if the sales process was fair ", "url": "https://www.businesswire.com/news/home/20260624581199/en/Catalyst-Pharmaceuticals-Investor-Alert-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Catalyst-Pharmaceuticals-Inc.---CPRX", "source_name": "Business Wire", "published_at": "2026-06-24T18:39:35", "published_display": "24 Jun 2026 18:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals to Be Acquired by Angelini Pharma in All-Cash Merger \u2013 Key Details from 8-K Filing", "summary": "Catalyst Pharmaceuticals, Inc. has announced a definitive merger agreement with Angelini Pharma S.p.A., where Catalyst will become a wholly-owned subsidiary of Angelini Pharma. The all-cash transaction is expected to close in the third quarter of 2026, subject to customary closin", "url": "https://www.minichart.com.sg/2026/06/24/catalyst-pharmaceuticals-to-be-acquired-by-angelini-pharma-in-all-cash-merger-key-details-from-8-k-filing/", "source_name": "Minichart", "published_at": "2026-06-24T01:39:36", "published_display": "24 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals merger cleared HSR waiting period as closing targets Q3 2026", "summary": "Catalyst Pharmaceuticals announced that the FTC granted early termination of the HSR waiting period for its merger with Angelini Pharma. This regulatory clearance, granted on June 16, 2026, paves the way for the merger, which is expected to close in Q3 2026, subject to customary ", "url": "https://www.tradingview.com/news/tradingview:ac6710b85ee91:0-catalyst-pharmaceuticals-merger-cleared-hsr-waiting-period-as-closing-targets-q3-2026/", "source_name": "TradingView", "published_at": "2026-06-23T21:10:58", "published_display": "23 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 62, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxOTkY3M1RhV2VaY25Fb1BDSWRmSWxDNTNXMnczT3JGd2JZVWJzcFJPc3JOaW1QWUttRXFNZ0RiV1dIeVVkYWZScUhFVi1PSnVqcjVuRzRqdEpGOUhtdW94VHVmdFlHNG9KOUhSX1dVZHFPNVY2UnRYOWpFRkZqbzE3Y2EwWjU0Z0doRHdhekR2T1ZVdw?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOaGx3REtjYzNHbEJ2WUFQblh3STF4blV3R1RhejhZNHVVUGFEU1djR2txY0xWVmNicDhUdGk5MkF1blVoTjkxUDRIRlBDNS02NW16a1E5c2c4dXBVQWtNMnFYbHdXS29EWWdfTVhldEc4Zy02ZEFWa29YTkJkRTRfcDdBVmdoWUhSb20xRExFNWhjN29yVEN1WkxiU2RWbWItRGxYUVdkNTh2eGJHcnN1MUxlWWVoSnl4REhOMVRVZnJtZw?oc=5", "source_name": "TradingView", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals stock (US14888U1016): Angelini Pharma to buy CPRX for $4.1 billion in cash", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPTGVCNGMxUUR1eTIyRFhEa3pjQXpTTHFpVTB4YVRVSGNkeDl3elE3SnUwUnlTTWZnd3VuTldyYW5TcG93a1RIRUsxS1VqUmRTVnlwLTkzVUI5MHAtVDlmNGFPUUNnTTVjOWlXMlJkdHMxQkcwNVlJYVlPZmVpMnBfTmZDTURwQUs2TERoeEJxLUVNTTgxUnB2a1lSa2RCYThJekVRcTVTZXZNOXNVSUlTdGk5M1dhTnlHTDlzN0ItOC1QbWdFanpMMU5R?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE1aUlhjcUFFaWozUjNSOEY1VFN2YnNyWlM0ZVVtQnQtUkZuMWpZZXpwRUhpTlpjdUtVaEU1QzJtUmdzSGsxSHg3UThxZThCNVRkSXc3MHNySUJkNXZRM25hRTZYd3hWY0dEczlKY0gtU3RCRVNxSXh0VXpiSVZHV0E?oc=5", "source_name": "qz.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Angelini to Expand into US Rare Disease Market with Catalyst Acquisition", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNSmlVc29vT0I5eWp1X0VLUmZJdkNpRzVNVTJvR2g1TWNJXzVfaEEwQ3lBdXV4S0lWTDR4Z2M1QU16VU5xOUVmOWVpUWZRdm12VGRwSVdIdGxXMXZTbU1WRUxieVRUamt6dDVXOEcyS2xjYm0tTGlzc0M2QXJrWFZtZU84Vms1bm1nbFk0ZHNNNUNiTmxFaDVKV2x1WWp1bmltTndzOEI5Mi1xeW0zMThrRVFBWDVwZ2M?oc=5", "source_name": "Pharmaceutical Commerce", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Angelini finds Catalyst for its US growth ambitions with $4.1B buyout", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPVmUzTHMzeXpKRTF2c0VTLTFnaUh6T0JBbUhlNEtDaUVvUV9MWVVoanYxazlYR190YkFiX3d6ZlowZ2xJZ090cHdYUmNpeW04MkRxdUk5Rl9MODVJQUN3bVQtUWpZbDlFd1JuU1pYYzdNOXI2eFFDSkZwbTBlY3FoSHJqN1JsaVFMSHRtOXg0R1l3d250T25oTGV3?oc=5", "source_name": "Fierce Pharma", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Seeking Clues to Catalyst (CPRX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPbjZTMHRYSWp1aHVtSy1uMXphbm5sTDZwRVNPNU9QZy1GUUV6M1dRaXB3UnhMZGNuUzY5eEJ0ak1aNjlvRmFnY09OWkFGRDRkUEI1bmpIQU1fTTBpQ1ZTQVlZU24tQlhzcnJNOXdhTXFISl9XOUNWTDZ5Q1kzVVhPalhTZEhZc1NhRmM3U3NPcFBhZ1UxYjJkZDg2Zw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNRF81ZHNTOGNWbFh6OTBpN01TMm5hTTRZdUtqTFZ4ZjYxeWQ5cHd6NFQ4S2JQNWg3V1ZEUmVhSW5hYVVNY1gxanVKaXlzQ05lLXFqWURILXV2OVh3RzVFdy1zb2JXanM4QU5sc09kU0N0Nkd5ODAxc0RkTnNDU1VITUNOQUo4ZE12bm5hSlZpWjEyZzVreUFsZHF4Ul91NEtrTjVhWkxSUVhsLTYwTGc?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst (CPRX) is on the Move, Here's Why the Trend Could be Sustainable", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOa3d6dFpYZmhoczNUM0Zid3NOMnlFNXRMRFZLRzNQUUdFdEZEZS1xd3ktWnl0QkcwOER2RWU0WjRkTjd1NUpSUGtvWUF2RWVYa3RwZEM5VHk4TlplcGVlYy1VMUxicXB3MG0tZHpub1Zqa05XMlY0TXJMQS1EUnp2a25lakV5WTFiLVZBaGE4ZDhTMGhTVEJYdA?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Stronger Firdapse and Agamree Momentum Require Action From Catalyst Pharmaceuticals (CPRX) Investors?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Catalyst (CPRX): Can Its 6.7% Jump Turn into More Strength?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPcF8tSnhCbVV5MzNVLWktV2psOXZaM1E4NGhxaGhReExOTmxFbGJRQWJwa0ZjYVpuTE9BWnhqV2tBY1kyVjlIemxzZVhWXzc2d0NXV0JSS0w4TFVMdHpSX2ZFR19mZE81VHdERTdBVkVISS1mNy1mLWlLMVRPWmpQS3V6OE5HbUZ1X2dxdmtZRW5lVjV0MnpGZW13?oc=5", "source_name": "Market source", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQOFNTZy11MHpWc1NCaEQ0ZllCeDVMQWRnSXNKLUdCU0xSZFVnWVZpNU1BRnA3UVE2WHI5WFlJZWJaNXhvbG54ak9YZWs5cjRtM3I4MWVMRUMyVzBDUkV6QUx2SW16OG9hLVYzVTFVUnoxQmNZblgwOXZ4MlBkUk9JYjFyelhHXzVySkdOR3p4MFVXY3g5MWx3OXNhNVNERWd0RXVkNXhtUnBuWVlmOEVsNWtUWTVyRmZFSjJNcU40SXR6cUgwT0R3c2ZWeng2R05L?oc=5", "source_name": "ChartMill", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top Affordable Growth Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxORFoxUjdrR1h4VDRiZEhueDU2RDc1aURkRlV5aThITDJjY2ZRNVJ1YnZldk80VC1NeWh1NEZ1NnQ1WWt2MDdqVUNoRU9YNzZaUmQ4RTFsTW5pYUNYbkdHdTMzZ0pxUGFZV0YtRGNZaUtUT3FYYnF5REVPMXF2eTlnUTJNUW1GanpCU01lQ2QxTEQ1SC1Gcm14V1REdkQyT0VwZjdJVnZfbWIwdlZjODYwQ1dfdGUtaVJfWGU2TnVJUC0yVDB2RU92VENkaHI?oc=5", "source_name": "ChartMill", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAJBVV95cUxObmp0dXNWNW9Ub2lLMkEyUWpvbzJQMzhMRGhyV1lMb281clFDa0FZcXBKSEk4d01qcmY4QVdZV3gyNEd1RFNPR204eVJWeFBTeEVmNjg2MG1NMzlKV2JINmltWGhGM0RXSVV1czhDVWtZNXhlRmZZZTBIVVZGTGdkZktYdHdkZWlHalFjc1g1OFYySUJIcnNyeGktbG9tMWJ1V1k2NnZBV1VDbVZMNkhLa0VidTQxZEFLUXJmdUdLc3hvdkFjcmtGN19Oa3pqMmY1aEZvOXhQSzZvUnRNbmJpMUZOM3FYZjd0TXAtNzBBVFVfLVlZMUoxbzVGOHFGVE81S2t2bENhRHlQbzNZdDNZd2dLWFZKN1EtczBlYnZCX291VjdTbG9GVTJ1LTY?oc=5", "source_name": "TradingView", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Catalyst Pharmaceuticals (CPRX) Still Attractively Priced After Recent Share Price Stability?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQdk1PT0U2TnM5eHJ0TkJ0eVRmMlA3LUlMTzBpNzFlUE9MWktTYVhwUGs1Mk4zSFBXVEsyc3RSam1Fem1KUS1uX0JSVE52Tk5MQkE1R3JYV0F4Yk5BbjZ2NFBlYThld1Z1bkZFMXFVVHBVQVRwXzZkLWg5dHVWRnBRVUNkNUprd25FcmpwTWM4U20zVkdLdWp4eWp5NzAzNWhCMURfVTBlNFl5cVlIWVZ1ZmF6SQ?oc=5", "source_name": "Market source", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNVnlmXzk4UlQ0ZW5zQmc4UHBZWkM3SjAySXpZMWlyREJIQ0VzRHdac0kweEFMY2N2TWVqUEFBVy1RRzhwU3g4XzJEdUpJZTRxWUlGdFNzelJwOENuYUFaV19pUDhHUUNJY1dPaUxNTTJXcU95d3Nmb0VyRHlPbV9RWnFGby02bDI2X1RJejczZTU4Y1dfNWJhNG5IYzZ6NVFxeU5pOEgzZ3lEOXczWXc?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQbDQ2aEYxNlo3MHlwN3hfZTZ4eFRNem9FRGd5b3ZOOWhYdmpNZmJ2azdTdURVQnh1dzNENDVQa3JRbktvNlVuc04xbmx1eXZnQk5ncW5WTHVOUjFLNDc4aFpyMU5DMC1OSE1mSlVOSERVNjJidUdvM1FPelRLQjRDdnFnNTJBU2FaN1VSVTdGNHRGZWhpME1XN2FiUU0xOFVxTFA0YUFxOC1yRnRkUXFiV3E2eUFiY1R5SGc?oc=5", "source_name": "TradingView", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPQ0ExclBkRW5FM25Kcmt3YUhleFhQQ2gtYVVJSEE0UHNhYWlvRTF4eUd1Qy01M3ZGbnVHV1NXQU43akR5TGdQMWZ1cGRzSGQ1eUdKSGlNT2Zwd0NxTmpsd0tTeXhiUG5GWWIzQWxLNlNnOWdJZ1B3XzhhaTIzaVcyc0NTVkI5d2laYUNLSlZrNF85bHRNTjdfN0dCUDB0LTQ?oc=5", "source_name": "Finviz", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs (CPRX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQSG1Lb1d5Nk54Z0dlOU1JMUR5VmpycURvVXZjajlCTFgwb3g2bV9tcmloZ1A1aF9IWTlZMDhfZThvcjZfNjJjVngyWWRnQmJ6SXJiWUprSWlSUTVQVm5CNFlTQlhmRFRFb2ZERDAzQnBkcklTblNsenAyTGtMTzA5MFlTckJvLUI5NnJfY2YzMm9rblU0UGQ4a1N5aDQ3T0ZxMFNHdWJRRXhTeE5Wbkt1UGp1M0tad0I3dFotYmtR?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 105, "total_relevant": 63, "sentiment_summary": {"positive": 27, "negative": 6, "neutral": 30, "score": 58, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 14.1, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 11.55, "count": 23}, {"event": "deals", "label": "Deals and strategy", "weight": 7.15, "count": 13}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 27, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 31.47, "latest_week": "2026-07-10", "one_week_move": 0.1, "four_week_move": 0.4, "twelve_week_move": 19.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.068708, "market_dynamics_buy_signal": false, "relative_strength": 11.762966, "fair_value_gap": 55.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 60.4131, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.1% over one week, +0.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 56, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "TradingView", "count": 9}, {"label": "Stock Titan", "count": 5}, {"label": "ChartMill", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Sahm", "count": 3}, {"label": "Quartr", "count": 3}, {"label": "GlobeNewswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 55}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 23}, {"label": "Deals and strategy", "count": 13}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "55", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.1% over one week, +0.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals"}], "updated_at": "2026-07-16T08:52:20.380739+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}